Smithkline Beecham Corporation

University College Cardiff Consultants Limited

Beecham Group Plc

David Drysdale Miller

Alan T Hudson

David Bell

Laddawan Chunchatprasert

Robin Patrick Attrill

Sadie Vile

Patrick Vivian Shannon

Paul Bamborough

David Harold Drewry

Carl J Rose

Michael John Alberti

Gillian Turner

Frances Finney

Ann Louise Walker

Paul Barraclough

Simon Thomas Barry

Carmel Horgan

Steven Ludbrook

Pierre P Debont

Patrick Vivian Richard Shannon

Laddawan Chuncharprasert

The present invention relates to aminopyrazine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such aminopyrazine derivatives are useful in the treatment of diseases associated with inappropriate tyrosine and/or serine/threonine kinase activity.

Aminopyrazine derivatives and compositions

The present invention relates to aminopyrazine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medcicaments. Such aminopyrazine derivatives are useful in the treatment of diseases associated with inappropriate tyrosine and/or serine/threonine kinase activity.

A method for the identification of a modulator of the interaction between latency asssociated peptide (LAP) of transforming growth factor &#x3b2;1 (TGF-&#x3b2;1) and the integrin ab, which method comprises: (a) providing, as a first component, LAP-&#x3b2;1 or a functional variant thereof (b) providing, as a second component, integrin abor a functional variant thereof (c) contacting the two components with a test product under conditions that, in the absence of the test product, would permit the two components to interact; and (d) determining whether the test product is capable of modulating the interaction between the first and second components, thereby to determine whether the test product is a modulator of the interaction between LAP-&#x3b2;1 and integrin ab.

[object Object]

This invention relates to the catalyst (III) and intermediates for its preparation in which M is a transition metal ion; A is a counter-ion if required; B, B&prime;, and E and E&prime; are independently selected from the group consisting of hydrogen aryl, C,alkyl, silyl or aryl-C,alkyl in which any aryl or alkyl moiety is optionally substituted or B&prime; and B or E&prime; and E together form a C,polymethylene link; with the proviso that only one of the carbons marked with an asterisk if a chiral center; R,, R,, R,, R,, R,, R,, R,, R,, R,and R,are independently hydrogen, alkyl or alkoxy

Process for expoxidizing prochiral olefins and a catalyst therefor and intermediates for making the catalyst

Tricyclic derivatives and their use as anti-cancer agents

The present invention relates to heterocyclic compounds which have been found to have anti-tumour activity. More specifically, the invention concerns pyrrolo[2,3-b]carbazoles and 1H-[1] benzothieno [2,3-f] indoles, methods for their preparation, pharmaceutical formulations containing them and their use as anti-tumour agents. The compounds have low toxicity against normal cell lines whilst exhibiting anti-tumour cell activity.

Antitumor tetracyclic compounds

Process for epoxidising prochiral olefins and a catalyst therefor and

Pyrrolo�3,2-b-!-carbazoles and 1H�1!benzothieno �2,3-f! indoles having

Heterocyclic compounds

Compounds and process

The present invention relates to a process for the preparation of 4-(6.sup.1 -methoxy-2.sup.1 -naphthyl)butan-2-one and to certain compounds for use in that process. British patent specification No. 1,474,377 discloses inter alia that 4-(6.sup.1 -methoxy-2.sup.1 -naphthyl)butan-2-one possesses useful anti-inflammatory activity. A particularly favored process has now been discovered that can be used to produce 4-(6.sup.1 -methoxy-2.sup.1 -naphthyl)butan-2-one in particularly good yield. The present invention provides a process for the preparation of 4-(6.sup.1 -methoxy-2.sup.1 -naphthyl)butan-2-one which process comprises the hydrogenation of a compound of the formula (I): ##STR1## wherein Ar is a 6-methoxy-2-naphthyl group; X and Y are each hydrogen atoms or together represent a second bond between the carbon atoms to which they are attached; and R is a group such that --CO.sub.2 R represents an ester group convertible by hydrogenation to a CO.sub.2 H group.

Chemical process for the preparation of 4-(6.sup.1 -methoxy-2.sup.1

The present invention relates to a process for the preparation of 4-(6.sup.1 -methoxy-2.sup.1 -naphthyl)butan-2-one and to certain compounds for use in that process. British Pat. Spec. No. 1,474,377 discloses inter alia that 4-(6.sup.1 -methoxy-2.sup.1 -naphthyl) butan-2-one possesses useful anti-inflammatory activity. A particularly favored process has now been discovered that can be used to produce 4-(6.sup.1 -methoxy-2.sup.1 -naphthyl) butan-2-one in particularly good yield. The present invention provides a process for the preparation of 4-(6.sup.1 -methoxy-2.sup.1 -naphthyl)butan-2-one which process comprises the hydrogenation of a compound of the formula (I): ##STR1## wherein Ar is a 6-methoxy-2-naphthyl group; X and Y are each hydrogen atoms or together represent a second bond between the carbon atoms to which they are attached; and R is a group such that --CO.sub.2 R represents an ester group convertible by hydrogenation to a CO.sub.2 H group.

Chemical Process

Growing community of inventors

Stevenage, United Kingdom

David Drysdale Miller